Overview

Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes

Status:
Completed
Trial end date:
2009-12-29
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in subjects with Type 2 Diabetes who are not well controlled on diet and exercise alone. The safety of this treatment will also be studied
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Bristol-Myers Squibb
Treatments:
Dapagliflozin